胸腺肽注射液联合头孢菌素类药物治疗老年慢性支气管炎急性发作期的有效性分析  

Analysis of the effectiveness of thymopolypeptides injection combined with cephalosporins in the treatment of acute exacerbations of chronic bronchitis in the elderly

作　　者：李芝兰 李国胜 LI Zhi-lan;LI Guo-sheng(Cadre Ward,No.985 Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army,Taiyuan 030001,China)

机构地区：[1]中国人民解放军联勤保障部队第九八五医院干部病房,030001 [2]中国人民解放军联勤保障部队第九八五医院呼吸科,030001

出　　处：《中国实用医药》2022年第11期30-33,共4页China Practical Medicine

摘　　要：目的分析胸腺肽注射液与头孢菌素类药物联合治疗老年慢性支气管炎急性发作期的有效性。方法88例老年慢性支气管炎急性发作期患者,按照随机数字表法分为参照组和观察组,各44例。参照组实施头孢菌素类药物治疗,观察组在参照组的基础上联合应用胸腺肽注射液治疗。比较两组症状改善时间、炎性指标[白细胞介素-8(IL-8)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平、临床疗效、肺功能指标(用力肺活量、第1秒用力呼气容积)水平、不良反应发生情况。结果观察组的肺啰音改善时间、咳嗽咳痰改善时间、呼吸困难改善时间、退热时间分别为(6.12±0.86)、(4.13±0.51)、(3.72±0.49)、(1.56±0.13)d,均明显短于参照组的(8.18±1.13)、(5.59±0.77)、(4.71±0.62)、(2.19±0.23)d,差异有统计学意义(P<0.05)。治疗前,两组IL-8、IL-6、TNF-α水平对比差异无统计学意义(P>0.05);治疗后,观察组IL-8、IL-6、TNF-α水平均明显低于参照组,差异有统计学意义(P<0.05)。观察组治疗总有效率94.45%明显高于参照组的81.82%,差异有统计学意义(P<0.05)。治疗前,观察组用力肺活量(2.86±0.27)L与参照组的(2.94±0.37)L对比差异无统计学意义(t=1.159,P=0.250>0.05);治疗前,观察组第1秒用力呼气容积(2.62±0.35)L与参照组的(2.49±0.31)L比较差异无统计学意义(t=1.844,P=0.069>0.05)。治疗后,观察组用力肺活量为(3.74±0.52)L,第1秒用力呼气容积为(3.43±0.26)L,均高于参照组的(3.32±0.46)、(3.12±0.34)L,差异有统计学意义(t=4.013、4.804,P=0.000、0.000<0.05)。观察组不良反应发生率稍高于参照组,但组间对比差异无统计学意义(χ^(2)=0.345,P=0.557>0.05)。结论老年慢性支气管炎急性发作期患者接受头孢菌素类药物联合胸腺肽注射液治疗能提高总体疗效,改善炎症反应,缩短症状改善时间。Objective To analyze the effectiveness of thymopolypeptides injection combined with cephalosporins in the treatment of acute exacerbations of chronic bronchitis in the elderly. Methods A total of 88elderly patients with acute exacerbation of chronic bronchitis were divided into reference group and observation group according to the random numerical table, with 44 cases in each group. The reference group was treated with cephalosporins, and the observation group was treated with thymopolypeptides injection on the basis of the reference group. Both groups were compared in terms of symptom improvement time, inflammatory indexes [interleukin-8(IL-8), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)], clinical efficacy, pulmonary function indicators (forced vital capacity, forced expiratory volume in the 1st second), and occurrence of adverse reactions.Results The improvement time of lung rales, cough and sputum improvement time, dyspnea improvement time and fever reduction time of the observation group were (6.12±0.86), (4.13±0.51), (3.72±0.49), and(1.56±0.13) d, which were significantly shorter than (8.18±1.13), (5.59±0.77), (4.71±0.62), and (2.19±0.23) d of the reference group, and the difference was statistically significant (P<0.05). Before treatment, there was no statisically significant difference in the levels of IL-8, IL-6 and TNF-α between the two groups (P>0.05). After treatment, the levels of IL-8, IL-6 and TNF-α in the observation group were significantly lower than those in the reference group, and the difference was statistically significant (P<0.05). The total effective rate of treatment in the observation group was 94.45%, which was significantly higher than 81.82% in the reference group, and the difference was statistically significant (P<0.05). Before treatment, there was no statistically significant difference in forced vital capacity between the observation group [(2.86±0.27) L] and the reference group [(2.94±0.37) L] (t=1.159, P=0.250>0.05). Before treatment, the forced expirat

关 键 词：胸腺肽注射液 头孢菌素 慢性支气管炎急性发作期 老年 

分 类 号：R562.21[医药卫生—呼吸系统]